Conflict of interest: Nothing to declare.
Loss of mismatched HLA in myeloid/NK cell precursor acute leukemia relapse after T cell-replete haploidentical hematopoietic stem cell transplantation
Article first published online: 25 JAN 2014
© 2014 Wiley Periodicals, Inc.
Pediatric Blood & Cancer
Volume 61, Issue 10, pages 1880–1882, October 2014
How to Cite
Kobayashi, S., Kikuta, A., Ito, M., Sano, H., Mochizuki, K., Akaihata, M., Waragai, T., Ohara, Y., Ogawa, C., Ono, S., Ohto, H. and Hosoya, M. (2014), Loss of mismatched HLA in myeloid/NK cell precursor acute leukemia relapse after T cell-replete haploidentical hematopoietic stem cell transplantation. Pediatr. Blood Cancer, 61: 1880–1882. doi: 10.1002/pbc.24962
- Issue published online: 19 AUG 2014
- Article first published online: 25 JAN 2014
- Manuscript Accepted: 6 JAN 2014
- Manuscript Received: 29 AUG 2013
- graft versus host disease;
- rare tumors;
- stem cell transplantation
Myeloid/natural killer cell precursor acute leukemia (MNKL) is an aggressive disease with a high relapse rate even after allogeneic hematopoietic stem cell transplantation (SCT). We report a patient with MNKL who had a donor lymphocyte infusion (DLI) for relapse after T cell-replete human leukocyte antigen (HLA)-haploidentical SCT, but relapsed again 20 months later with loss of mismatched HLA. This case suggests that a strong graft-versus-leukemia effect of haploidentical SCT can be expected in MNKL patients. In the haploidentical setting, DLI should be considered for patients with relapsed leukemia whose leukemic cells have not lost HLA cell surface expression. Pediatr Blood Cancer 2014; 61:1880–1882. © 2014 Wiley Periodicals, Inc.